The Inflation Reduction Act’s policy capping out-of-pocket costs for insulin to $35 for a month’s supply led to increases in the total number of insulin fills for Medicare beneficiaries, according to a new study from the USC Schaeffer Center for Health Policy & Economics and University of Wisconsin–Madison.
LEO-152020 by Leo Pharma for Atopic Dermatitis (Atopic Eczema): Likelihood of Approval
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes
October 28, 2023